Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 384
- Registration Number
- NCT03123770
- Locations
- 🇨🇳
Cancer institute, Hangzhou, Zhejiang, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1174
- Registration Number
- NCT03036488
- Locations
- 🇦🇺
Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia, Australia
🇺🇸Cedars Sinai Medical Center ( Site 0091), Los Angeles, California, United States
🇺🇸The University of Chicago Medical Center ( Site 0047), Chicago, Illinois, United States
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer, Epithelial
- Interventions
- Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV)Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV)
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Groupe Hospitalier Diaconesses Croix Saint-Simon
- Target Recruit Count
- 84
- Registration Number
- NCT03025477
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France
🇫🇷Institut Hospitalier Franco-Britannique, Levallois-Perret, France
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT03022123
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shi Jiazhuang, Hebei, China
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Prestige Biopharma Limited
- Target Recruit Count
- 503
- Registration Number
- NCT03013504
- Locations
- 🇧🇾
Minsk Clinical Oncological Dispensary, Minsk, Belarus
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇮🇹Modena Hospital, Modena, Italy
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Shi Yanxia
- Target Recruit Count
- 320
- Registration Number
- NCT03006614
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
- Conditions
- T Cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02987244
- Locations
- 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
- Conditions
- Portal Vein Tumor ThrombusHepatocellular Carcinoma
- Interventions
- Procedure: Stent and Iodine-125 seed strand implantationDevice: StentDevice: Iodine-125 seedOther: Gelatin sponge articles
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 253
- Registration Number
- NCT02971345
- Locations
- 🇨🇳
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer
- Conditions
- Stomach NeoplasmsGastric Cancer
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 40
- Registration Number
- NCT02949258
- Locations
- 🇨🇳
Research institue of general surgery, Jinling hospital, Nanjing, Jiangsu, China
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Dietary Supplement: Tocotrienol 300 mg x 3 daily
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02909751
- Locations
- 🇩🇰
Vejle hospital, Department of Oncology, Vejle, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.